Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of compounds targeting SARS-CoV-2 helicase

6 Dec 2022

Abstract excerpt

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to PARP inhibition in cancer therapy
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36561139
DOI: 10.3389/fchem.2022.1062352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of compounds targeting SARS-CoV-2 helicasePMID 36561139Read ↗

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 HelicaseSemantic proximity Read ↗

Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).Semantic proximity Read ↗

Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 HelicaseSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?Semantic proximity Read ↗

High throughput screening for SARS-CoV-2 helicase inhibitorsSemantic proximity Read ↗

What a twist: structural biology of the SARS-CoV-2 helicase nsp13Semantic proximity Read ↗

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Druggable targets and therapeutic development for COVID-19Semantic proximity Read ↗

Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRpSemantic proximity Read ↗

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.